Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141(+) dendritic cells to activate naïve and memory WT1‐specific CD8(+) T cells

OBJECTIVES: Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8(+) T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141(+) dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed exclus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Transl Immunology
Hlavní autoři: Pearson, Frances E, Tullett, Kirsteen M, Leal‐Rojas, Ingrid M, Haigh, Oscar L, Masterman, Kelly‐Anne, Walpole, Carina, Bridgeman, John S, McLaren, James E, Ladell, Kristin, Miners, Kelly, Llewellyn‐Lacey, Sian, Price, David A, Tunger, Antje, Schmitz, Marc, Miles, John J, Lahoud, Mireille H, Radford, Kristen J
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292901/
https://ncbi.nlm.nih.gov/pubmed/32547743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1141
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky